-+ 0.00%
-+ 0.00%
-+ 0.00%

Turn Therapeutics Presents GX-03 Phase 2a Data for Atopic Dermatitis

PUBT·11/10/2026 13:42:26
Listen to the news
Turn Therapeutics Presents GX-03 Phase 2a Data for Atopic Dermatitis
  • Turn Therapeutics expects first-quarter 2027 topline results from its Phase 2 GX-03 trial in moderate-to-severe atopic dermatitis.
  • Phase 3 initiation for atopic dermatitis is planned for mid-2027, with a potential commercial launch in 2029.
  • A 25-patient Phase 2a subgroup showed week-four vIGA-AD success of 61.5% with GX-03 versus 8.3% with vehicle.
  • The ongoing Phase 2b study targets approximately 120-136 patients, using enrollment criteria informed by stronger treatment separation in patients with severe itch.
  • GX-03 is also Phase 3-ready for onychomycosis, with trial initiation targeted for the second quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.